These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11269899)

  • 1. Safety of nimesulide, meloxicam and rofecoxib as alternative analgesics.
    Karakaya G; Kalyoncu AF
    Allergol Immunopathol (Madr); 2000; 28(6):319-21. PubMed ID: 11269899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
    Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
    J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs.
    Senna GE; Passalacqua G; Dama A; Crivellaro M; Schiappoli M; Bonadonna P; Canonica GW
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):393-6. PubMed ID: 14768525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Swaak AJ; Theunissen DJ
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1476-7; author reply 1477-8. PubMed ID: 11503322
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Houben JJ; Liem B
    Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2338. PubMed ID: 10589225
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative safety of meloxicam in NSAID-intolerant patients.
    Kosnik M; Music E; Matjaz F; Suskovic S
    Allergy; 1998 Dec; 53(12):1231-3. PubMed ID: 9930610
    [No Abstract]   [Full Text] [Related]  

  • 10. Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
    Çelik GE; Erkekol FÖ; Aydın Ö; Demirel YS; Mısırlıgil Z
    Allergol Immunopathol (Madr); 2013; 41(3):181-8. PubMed ID: 23031659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Degner F; Lesaffre E; Zeidler H
    Rheumatology (Oxford); 2004 May; 43(5):680-1; author reply 681-2. PubMed ID: 15103042
    [No Abstract]   [Full Text] [Related]  

  • 12. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.
    MacDonald TM; Morant SV; Goldstein JL; Burke TA; Pettitt D
    Gut; 2003 Sep; 52(9):1265-70. PubMed ID: 12912856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
    Kruse R; Ruzicka T; Grewe M
    Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib- and rofecoxib-induced delirium.
    Macknight C; Rojas-Fernandez CH
    J Neuropsychiatry Clin Neurosci; 2001; 13(2):305-6. PubMed ID: 11449042
    [No Abstract]   [Full Text] [Related]  

  • 16. Meloxicam-induced erythema multiforme.
    Nikas SN; Kittas G; Karamaounas N; Drosos AA
    Am J Med; 1999 Nov; 107(5):532-4. PubMed ID: 10569318
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Huang WF; Hsiao FY; Tsai YW; Wen YW; Shih YT
    Drug Saf; 2006; 29(3):261-72. PubMed ID: 16524325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
    Quiralte J; Sáenz de San Pedro B; Florido JJ
    Ann Allergy Asthma Immunol; 2002 Jul; 89(1):63-6. PubMed ID: 12141722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
    Harirforoosh S; Aghazadeh-Habashi A; Jamali F
    Clin Exp Pharmacol Physiol; 2006 Oct; 33(10):917-24. PubMed ID: 17002668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition.
    Brater DC
    Am J Med; 1999 Dec; 107(6A):65S-70S; discussion 70S-71S. PubMed ID: 10628595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.